Analysis and improvement measures of rational use of proton pump inhibitors for injection by clinical pharmacists
Main Article Content
Keywords
Proton pump inhibitors for injection, Clinical pharmacist, Rational drug use, Omeprazole, Esomeprazole
Abstract
Objective: To analyze the irrational use of proton pump inhibitors for injection in clinic and its causes, and to promote the standardized use of proton pump inhibitors in hospital by clinical pharmacists by taking corresponding intervention measures. Methods: The use of proton pump inhibitors from January to March 2024 was collected through the rational drug use system of The Second Affiliated Hospital of Xuzhou Medical University, and the problems of irrational drug use during the use of proton pump inhibitors were classified, statistically summarized. Results: From January to March 2024, a total of 2363 inpatients in The Second Affiliated Hospital of Xuzhou Medical University were prescribed proton pump inhibitors for injection, including 1321 orders for esomeprazole for injection, 804 orders for omeprazole for injection, 166 orders for iprrazole for injection, 64 orders for Pantoprazole for injection, and 8 orders for rhaprazole for injection. There were 55 cases of unreasonable medical orders for drug use, and the irrational types of clinical drug use mainly included 24 unsuitable indications (43.64% of unreasonable medical orders). The selected drugs were not suitable in 7 cases (unreasonable medical advice accounted for 12.73%); Inappropriate usage and dosage in 19 cases (34.55%); There were 3 cases (5.45%) of unreasonable combination and 2 cases (3.64%) of unreasonable repeated administration. Conclusion: There are many unreasonable situations in the use of proton pump inhibitors for injection in our hospital. Clinical pharmacists will be committed to promoting hospitals to introduce a number of initiatives to standardize the use of proton pump inhibitors and improve the level of rational use of proton pump inhibitors.
References
injection[J]. China Clinical Research,2024, 24 (in Chinese)37 (02) : 252-255 + 260.
2. Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023 May;59(2):115-127. doi: 10.4068/cmj.2023.59.2.115. Epub 2023 May 25. PMID: 37303818; PMCID: PMC10248387. 37(02):252-255+260.
3. Xiong L, Liu HM, Li C, et al. Intervention effect analysis of the application of proton pump inhibitors in hospitalized patients in our hospital before and after carrying out prescription comments, medical insurance control costs and DRGs by clinical pharmacists [J]. Chinese journal of hospital pharmacy, 2019, 33 (4) 6:394-398. The DOI: 10.13286 / j.carol carroll nki chinhosppharmacyj. 2019.04.18.
4. Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors.
Int J Clin Pharm. 2015 Oct;37(5):709-16. doi: 10.1007/s11096-015-0150-z. Epub 2015 Jun 23. PMID: 26100836; PMCID:
PMC4594082.
5. National Health Commission. Opinions on Strengthening Pharmaceutical Administration in Medical Institutions and Promoting Rational Drug Use [EB/ OL].(2020-02-21).[2023-07-20].
6. Li CX, Wang Y, Ren Z, et al. Evaluation on the rational use of proton pump inhibitors based on the Guidelines for Clinical Use of Proton Pump Inhibitors(2020 edition) [J]. Journal of Clinical Pharmacotherapy, 2002,20(12):71-75.
7. Sun F, Ma JM, Yang JJ, et al. Effects of pharmacist intervention on rational use of proton pump inhibitors[J]. Primary Medicine
Forum,2023,27(01):126-128+138. (in Chinese) DOI:10.19435/ J.1672-1721.2023.01.041.
8. Liu JF, Jiang JY. Chinese expert consensus on prevention and treatment of post-traumatic stress ulcer [J]. Chinese Journal of
Neurosurgery, 2018 7, volume 34, 7 P649-651.
9. Expert advice on prevention and treatment of stress ulcer (2018 edition)[J]. Chinese Medical Journal,2018,98(42):3392-3395.
(in Chinese).
10. Guidelines for primary diagnosis and treatment of gastroesophageal reflux disease (2019) [J]. Chinese Journal of General
Practitioners,2019,18(7):635-641.(in Chinese)
11. 2022 Chinese National Clinical Practice Guideline on Helicobacter pylori Eradication Treatment [J]. Chinese Journal of
Digestion,202,42(11):745-753. (in Chinese)
12. Expert consensus on prophylaxis of proton pump inhibitors [J]. Chinese Journal of Medical Doctors,2018,20(12):1775-1778.
(in Chinese)
13. Guangdong Pharmaceutical Society. Expert guidance on prophylactic use of proton pump inhibitors and prescription
simplification [J/OL]. Pharmacy Today [2019-07-01].
14. Wang G, Li ZL, Xie XL, et al. Expert consensus on the proper application of proton pump inhibitors in children(2019 edition) [J]. Chinese journal of practical pediatrics, 2019, (12) : 977-981. The DOI: 10.19538 / j. k2019120602.
15. Consensus on diagnosis and treatment of functional dyspepsia in Chinese children (2022 edition) [J]. Chinese Journal of
Pediatrics,202,60(8):751-754. (in Chinese)
16. Jiang WQ, Ba Y, Feng JF, et al. Chinese expert Consensus on Prevention and treatment of nausea and vomiting associated with tumor drug Therapy (2019 edition)[J]. Chinese Journal of Frontiers in Medicine,2019,11(11):16-26.
17. Li H, Li N, Jia X, Zhai Y, Xue X, Qiao Y. Appropriateness and Associated Factors of Stress Ulcer Prophylaxis for Surgical Inpatients of Orthopedics Department in a Tertiary Hospital: A Cross-Sectional Study. Front Pharmacol. 2022 Jun 2;13:881063. doi: 10.3389/fphar.2022.881063. PMID: 35721126; PMCID: PMC9203048.
18. NCCN Clinical Practice Guidelines in Oncology : Antiemesis (Version 2.2023)
19. Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM,
Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H,
Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scotté F;
participants of the MASCC/ESMO Consensus Conference 2022. Electronic address: [email protected]. 2023 MASCC
and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open.
2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11. PMID: 38458657; PMCID: PMC10937211.
20. Sawaid IO, Samson AO. Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. Journal of Clinical Medicine. 2024; 13(7):1970.
21. Qian Y, Ni Z H. Novel understanding about proton pump inhibitors related renal injury [J]. China Blood
Purification,2018,17(03):197-200. (in Chinese)
22. Pang LF, Hua S. Analysis of the reasonability of the use of intravenous proton pump inhibitors and its in-hospital control [J].
Shanghai Journal of Medicine, 2019,45(03):25-27+54.
23. Liu L, Yu Y, Fan Q, Wu Z, Li X, Luo H. Impact of proton pump inhibitor management committee’s multifaceted interventions on acid suppressant prescribing patterns in outpatient and emergency departments. BMC Health Serv Res. 2022 Mar 29;22(1):417. doi: 10.1186/s12913-022-07820-x. PMID: 35351121; PMCID: PMC8966235. 24. Hammond DA, Killingsworth CA, Painter JT, Pennick RE, Chatterjee K, Boye B, Meena N. Impact of targeted educational
interventions on appropriateness of stress ulcer prophylaxis in critically ill adults. Pharm Pract (Granada). 2017 Jul-
Sep;15(3):948. doi: 10.18549/PharmPract.2017.03.948. Epub 2017 Aug 15. PMID: 28943978; PMCID: PMC5597806.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.